News
FluMist(r) Begins Shipping for 2010-2011 Influenza Season
MedImmune announced today that it has begun shipping FluMist(r) (Influenza Vaccine Live, Intranasal) to influenza vaccine distributors who service health care providers throughout the United States.
MedImmune expects to provide approximately 15 million doses of its trivalent (three-strain) nasal spray flu vaccine for the 2010-2011 influenza season through a variety of private health care practices, public health departments, school-located vaccination programs, military bases, and other venues.
Uroplasty Receives New Patent for Implantable Neuromodulation System and Method
Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today the issuance of United States Patent No. 7,729,772 which covers a method for using an implantable neuromodulation system in the treatment of urinary incontinence by neuromodulation or stimulation of the tibial nerve. The neuromodulation system includes a portable, external transmitter and a receiver implanted subcutaneously in the leg or ankle near the tibial nerve.
Urgent® PC and Macroplastique® Presentations
Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that at the May 28-June 2, 2010 Annual Meeting of the American Urological Association (AUA) in San Francisco, CA, there will be two presentations on Uroplasty's Urgent® PC Neuromodulation System and one on its Macroplastique® urethral bulking agent.
Urgent PC presentations:
-- "Percutaneous Tibial Nerve Stimulation (PTNS): A Multi-Center,
New Hope for Patients Suffering From Bladder Control Problems
Dr. Robert Pugach, Medical Director of Pacific Coast Urology Medical Center recently travelled to Minneapolis to meet with Medtronic engineers to discuss ideas for advances in InterStim© Therapy, a 30 minute procedure that can end bladder control problems like frequent, urgent or nighttime urination.
Medline Awarded New Novation Urological Agreement Featuring Innovative CAUTI Prevention Tools
Medline Industries, Inc., the nation's largest privately held manufacturer and distributor of medical supplies, today announced a three-year agreement with leading healthcare supply contracting company Novation for urological products. Under the terms of the new agreement, Medline will be the single NOVAPLUS® supplier for more than 25,000 members of VHA Inc., the University HealthSystem Consortium, and 5,500 members of Provista, representing more than 28,000 sites. The agreement is part of Novation's "Patient Care" standardization program and is effective July 1, 2010.
Boston Scientific Strengthens Marketing Alliance With BHN
Boston Scientific Corporation today announced that it has entered into a four-year exclusive marketing agreement with Bladder Health Network (BHN), a privately held company offering advanced testing solutions for urinary incontinence. BHN offers an integrated diagnostic solutions platform that combines software, staffing, equipment, supplies and results analysis, providing physicians and their patients with greater access to testing, interpretation and treatment options for urinary incontinence and other problems related to the urinary system.
Vitala Continence Control Device Receives Medical Design Excellence Award
ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today that the VitalaTM Continence Control Device (CCD) has received a 2010 Medical Design Excellence Award.
New Data Shows Budget Impact of Fecal Management System in Hospital ICU
ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new study results that demonstrate hospitals could realize substantial savings by substituting Flexi-Seal® FMS for traditional fecal management methods. The cost savings are mainly due to a reduction in time required for nursing staff to manage fecal incontinence.(1) This study was presented at the 23rd Annual Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS) in Orlando, Florida.
Renessa® Treatment for Incontinence Now Covered
Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that effective April 2, 2010 Blue Shield of California covers the Renessa® treatment for non-pregnant women diagnosed with moderate to severe stress urinary incontinence (SUI) who are unable or unwilling to undergo surgery.
SCA Launches 'Be TENAcious' Campaign
More than 1 in 4 women over 40 face bladder control issues and many are suffering in silence and not seeking out solutions that can enable them to lead the lives they desire. That is why SCA, through its TENA® brand, is launching its latest advocacy campaign designed to open a dialog, inform and inspire women to overcome the challenges of bladder control issues with a simple message - Be TENAacious!